Home » News » Drug Sponsors » Pfizer, Allergan break up, merger cancelled

Pfizer, Allergan break up, merger cancelled

Wednesday, April 6, 2016

Pfizer and Allergan have mutually agreed to terminate their merger agreement. The companies had spent time conducting a review of the U.S. Department of Treasury’s recent announcements on tax law changes.

The decision to break up the merger was driven by the actions announced by the U.S. Department of Treasury on April 4, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement.

The deal, previously valued at $160 billion, would have allowed Pfizer to avoid U.S. taxes on a large portion of profits stored overseas. Allergan is Ireland-based and the merger would move the companies legal domicile out of the U.S.

Though the original agreement called for a $400 million breakup fee, it’s likely the fee will be less based on the circumstances.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!